1 doctor weighed in:

What are the most promising treatments for t-cell prolymphocytic leukemia?

1 doctor weighed in
Dr. Herbert Duvivier
Internal Medicine - Hematology & Oncology

In brief: Campath (alemtuzumab)

T-cell pll is considered a relatively chemotherapy resistant disease.
Although treatments with chop, cop, fludarabine, etc are used they usually do not result in long term control of the disease. More recently Campath (alemtuzumab) has been used with increased success. Lastly, bone marrow transplant once in remission is being looked at as a possible consolidation therapy with some promise.

In brief: Campath (alemtuzumab)

T-cell pll is considered a relatively chemotherapy resistant disease.
Although treatments with chop, cop, fludarabine, etc are used they usually do not result in long term control of the disease. More recently Campath (alemtuzumab) has been used with increased success. Lastly, bone marrow transplant once in remission is being looked at as a possible consolidation therapy with some promise.
Dr. Herbert Duvivier
Dr. Herbert Duvivier
Thank
Get help from a real doctor now
Dr. Peter Kurzweil
Board Certified,
46 years in practice
16M people helped
Continue
108,000 doctors available
Read more answers from doctors